News
Today, CADTH has issued final recommendations for:
inotersen (Tegsedi)
Indications: hereditary transthyretin amyloidosis
Recommendation: Reimburse with clinical criteria and/or conditions
For more information
CADTH has received the following notice(s) of pending drug submission(s).
Brand name
Halobetasol propionate and tazarotene
Generic name
Duobrii
Manufacturer
Bausch Health, Canada Inc.
Indication(s)
Psoriasis, moderate to severe plaque
Project Number
SR0638-000
Call for patient...
Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.
Today, CADTH has issued final recommendations for:
Nerlynx for Hormone Receptor-Positive Breast Cancer
Funding Request: For patients with HER2-positive, hormone receptor-positive breast (HR-positive) cancer who have completed adjuvant trastuzumab-based therapy within the past 12 months.
Recommendation: Do not reimburse
Notification to implemen...
Today, CADTH has issued final recommendations for:
lanadelumab (Takhzyro)
Indications: Hereditary angioedema, prevention
Recommendation: Reimburse with clinical criteria and/or conditions
For more information
certolizumab pegol (Cimzia)
Indications: Psoriasis, moderate to severe plaque
Recommendation: Reimburse with clinical criteria and/...
